REDWOOD CITY, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the second quarter ended June 30, 2017.
Second Quarter and Recent Highlights
Executed strategic reorganization in April, reducing sales headcount by approximately 50% and resulting in a significant reduction in cash usage
